Core Viewpoint - On October 10, 2023, Ruimait experienced a 2.91% increase in stock price with a trading volume of 123 million yuan, indicating positive market sentiment towards the company [1]. Financial Performance - For the first half of 2025, Ruimait achieved a revenue of 544 million yuan, representing a year-on-year growth of 42.30%. The net profit attributable to shareholders was 131 million yuan, also reflecting a growth of 42.19% [2]. - Cumulative cash dividends distributed by Ruimait since its A-share listing amount to 228 million yuan [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders in Ruimait decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [2]. - On October 10, 2023, Ruimait's financing buy-in amounted to 12.20 million yuan, with a net buy of 3.00 million yuan, indicating strong investor interest [1]. - The total balance of margin trading for Ruimait reached 109 million yuan, accounting for 2.25% of its market capitalization, which is above the 50th percentile level over the past year [1]. Business Overview - Ruimait, established on July 27, 2001, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The revenue composition of Ruimait includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Ruimait [3].
瑞迈特10月10日获融资买入1219.67万元，融资余额1.08亿元